GDTC
NASDAQCytoMed Therapeutics Limited
Price$0.86-0.12 (-11.94%)
2026-07-162026-10-16
News · 26 weeks16+100%
2026-04-262026-10-18
Mix590d
- Insider2(40%)
- SEC Filings2(40%)
- Other1(20%)
Latest news
25 items- SECSEC Form 6-K filed by CytoMed Therapeutics Limited6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
- PRCytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencySINGAPORE, Oct. 09, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (the "Company") (NASDAQ:GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies, today announced that on October 6, 2026, the Company received a notice from the staff of the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC ("Nasdaq") stating that for the last 30 consecutive business days, the closing bid price of the Company’s ordinary shares (the "Ordinary Shares") was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listi
- SECSEC Form 6-K filed by CytoMed Therapeutics Limited6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
- INSIDERAmendment: Director Choo Chee Kong bought $300,000 worth of ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED (200,000 units at $1.50), increasing direct ownership by 46% to 630,324 units (SEC Form 4)4/A - CytoMed Therapeutics Ltd (0001873093) (Issuer)
- INSIDERSEC Form 4 filed by Director Choo Chee Kong4 - CytoMed Therapeutics Ltd (0001873093) (Issuer)
- SECSEC Form 6-K filed by CytoMed Therapeutics Limited6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
- INSIDERDirector Choo Chee Kong bought $128,778 worth of Ordinary Shares (112,000 units at $1.15), increasing direct ownership by 35% to 430,324 units (SEC Form 4)4 - CytoMed Therapeutics Ltd (0001873093) (Issuer)
- SECSEC Form 6-K filed by CytoMed Therapeutics Limited6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
- INSIDERNew insider Toh Keng Kiat claimed ownership of 4,000 units of Ordinary Shares (SEC Form 3)3 - CytoMed Therapeutics Ltd (0001873093) (Issuer)
- INSIDERNew insider Choo Chee Kong claimed ownership of 2,587,746 units of Ordinary Shares (SEC Form 3)3 - CytoMed Therapeutics Ltd (0001873093) (Issuer)
- INSIDERNew insider Yew Chak Hua claimed ownership of 2,469 units of Ordinary Shares (SEC Form 3)3 - CytoMed Therapeutics Ltd (0001873093) (Issuer)
- INSIDERSEC Form 3 filed by new insider Leong Mark Kei Wei3 - CytoMed Therapeutics Ltd (0001873093) (Issuer)
- INSIDERNew insider Goh Yvonne claimed ownership of 25,781 units of Ordinary Shares (SEC Form 3)3 - CytoMed Therapeutics Ltd (0001873093) (Issuer)
- INSIDERNew insider Tan Yoong Ying claimed ownership of 25,781 units of Ordinary Shares (SEC Form 3)3 - CytoMed Therapeutics Ltd (0001873093) (Issuer)
- SECSEC Form 6-K filed by CytoMed Therapeutics Limited6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
- SECSEC Form 6-K filed by CytoMed Therapeutics Limited6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
- SECSEC Form 6-K filed by CytoMed Therapeutics Limited6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
- SECSEC Form 6-K filed by CytoMed Therapeutics Limited6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
- SECSEC Form 20-F filed by CytoMed Therapeutics Limited20-F - CytoMed Therapeutics Ltd (0001873093) (Filer)
- SECSEC Form 6-K filed by CytoMed Therapeutics Limited6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
- PRCytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical ProgressSINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today issued a statement to address recent statements containing inaccurate and misleading claims regarding the Company's research programs, clinical progress, and operations. CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company's scie
- SECSEC Form 6-K filed by CytoMed Therapeutics Limited6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
- PRCytoMed Therapeutics' new year update and seeks shareholders' feedback on proposal to improve shareholder value for their patient capitalSINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to update shareholders as we enter a new exciting year in 2026. As mentioned in previous announcements, CytoMed through new subsidiary LongevityBank is also diversifying its product pipeline through the process development of clinical-grade cord blood-derived Natural Killer cells. In so doing, it will
- SECSEC Form 6-K filed by CytoMed Therapeutics Limited6-K - CytoMed Therapeutics Ltd (0001873093) (Filer)
- PRCytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in MalaysiaSINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today announced that it has entered into a Memorandum of Understanding with Universiti Malaya Medical Centre ("UMMC") a teaching hospital under Universiti Malaya to establish a multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of CytoMed's patented allogeneic unmodified Gamma
GDTC FAQ
5 questionsWhere does GDTC stock trade?
CytoMed Therapeutics Limited (GDTC) is listed on NASDAQ.What sector and industry is GDTC in?
CytoMed Therapeutics Limited operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did CytoMed Therapeutics Limited go public?
CytoMed Therapeutics Limited (GDTC) completed its IPO in 2023.What companies are similar to GDTC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GDTC side-by-side with any of them on Quantisnow.How can I track GDTC on Quantisnow?
Quantisnow aggregates CytoMed Therapeutics Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GDTC to receive live email and push alerts on every new disclosure.